Sökning: (WFRF:(Patel Manesh R)) conttype:(refereed) > Ticagrelor versus C...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05641naa a2200769 4500 | |
001 | oai:lup.lub.lu.se:6b3b1873-d506-41ee-bb11-40100c077fff | |
003 | SwePub | |
008 | 230831s2017 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:uu-334966 | |
009 | oai:prod.swepub.kib.ki.se:134885761 | |
024 | 7 | a https://lup.lub.lu.se/record/6b3b1873-d506-41ee-bb11-40100c077fff2 URI |
024 | 7 | a https://doi.org/10.1056/NEJMoa16116882 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3349662 URI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1348857612 URI |
040 | a (SwePub)lud (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Hiatt, William Ru University of Colorado4 aut |
245 | 1 0 | a Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease |
264 | 1 | c 2017 |
500 | a Martin Björck (Uppsala Universitet, Institutionen för kirurgiska vetenskaper, kärlkirurgi) var National Lead Investigator för den svenska delen av studien och en av dessa ”Investigators” | |
520 | a BACKGROUND: Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events. Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.METHODS: In this double-blind, event-driven trial, we randomly assigned 13,885 patients with symptomatic peripheral artery disease to receive monotherapy with ticagrelor (90 mg twice daily) or clopidogrel (75 mg once daily). Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone previous revascularization of the lower limbs. The primary efficacy end point was a composite of adjudicated cardiovascular death, myocardial infarction, or ischemic stroke. The primary safety end point was major bleeding. The median follow-up was 30 months.RESULTS: The median age of the patients was 66 years, and 72% were men; 43% were enrolled on the basis of the ABI and 57% on the basis of previous revascularization. The mean baseline ABI in all patients was 0.71, 76.6% of the patients had claudication, and 4.6% had critical limb ischemia. The primary efficacy end point occurred in 751 of 6930 patients (10.8%) receiving ticagrelor and in 740 of 6955 (10.6%) receiving clopidogrel (hazard ratio, 1.02; 95% confidence interval [CI], 0.92 to 1.13; P=0.65). In each group, acute limb ischemia occurred in 1.7% of the patients (hazard ratio, 1.03; 95% CI, 0.79 to 1.33; P=0.85) and major bleeding in 1.6% (hazard ratio, 1.10; 95% CI, 0.84 to 1.43; P=0.49).CONCLUSIONS: In patients with symptomatic peripheral artery disease, ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular events. Major bleeding occurred at similar rates among the patients in the two trial groups. (Funded by AstraZeneca; EUCLID ClinicalTrials.gov number, NCT01732822 .). | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng |
653 | a Adenosine/adverse effects | |
653 | a Aged | |
653 | a Cardiovascular Diseases/mortality | |
653 | a Clopidogrel | |
653 | a Double-Blind Method | |
653 | a Female | |
653 | a Hemorrhage/chemically induced | |
653 | a Humans | |
653 | a Intermittent Claudication/drug therapy | |
653 | a Ischemia/drug therapy | |
653 | a Kaplan-Meier Estimate | |
653 | a Leg/blood supply | |
653 | a Male | |
653 | a Middle Aged | |
653 | a Peripheral Arterial Disease/drug therapy | |
653 | a Platelet Aggregation Inhibitors/adverse effects | |
653 | a Purinergic P2Y Receptor Antagonists/therapeutic use | |
653 | a Ticagrelor | |
653 | a Ticlopidine/adverse effects | |
700 | 1 | a Fowkes, F Gerry Ru University of Edinburgh4 aut |
700 | 1 | a Heizer, Gretchenu Duke University4 aut |
700 | 1 | a Berger, Jeffrey Su New York University4 aut |
700 | 1 | a Baumgartner, Irisu University of Bern4 aut |
700 | 1 | a Held, Peteru AstraZeneca, Sweden4 aut |
700 | 1 | a Katona, Brian Gu AstraZeneca, US4 aut |
700 | 1 | a Mahaffey, Kenneth Wu Stanford University4 aut |
700 | 1 | a Norgren, Larsu Örebro University4 aut |
700 | 1 | a Jones, W Schuyleru Duke University4 aut |
700 | 1 | a Blomster, Juuso4 aut |
700 | 1 | a Millegård, Marcus4 aut |
700 | 1 | a Reist, Craig4 aut |
700 | 1 | a Patel, Manesh R4 aut |
700 | 1 | a Gottsäter, Andersu Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups4 cre0 (Swepub:lu)medf-ago |
710 | 2 | a University of Coloradob University of Edinburgh4 org |
710 | 2 | a EUCLID Trial Steering Committee and Investigators |
773 | 0 | t The New England journal of medicineg 376, s. 32-40q 376<32-40x 0028-4793x 1533-4406 |
856 | 4 | u http://dx.doi.org/10.1056/NEJMoa1611688y FULLTEXT |
856 | 4 8 | u https://lup.lub.lu.se/record/6b3b1873-d506-41ee-bb11-40100c077fff |
856 | 4 8 | u https://doi.org/10.1056/NEJMoa1611688 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-334966 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:134885761 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.